1st Counsel – Lifestyle
Author:
ArriVent BioPharma, Inc.
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
March 17, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
March 5, 2026